cGAS–STING signalling in triple-negative breast cancer: a functional-state framework for biomarker-guided intervention
Abstract
Triple-negative breast cancer (TNBC) combines genomic instability with heterogeneous immune responses. Cyclic GMP–AMP synthase (cGAS) detects mislocalised DNA and produces cyclic guanosine monophosphate–adenosine monophosphate (cGAMP), which activates stimulator of interferon genes (STING). The resulting response can support antigen presentation or sustain inflammatory adaptation. This review interprets these divergent effects through four non-exclusive functional states: immune-productive activation, tumour-intrinsic attenuation, chronic inflammatory rewiring and extracellular cGAMP-restricted signalling. We connect DNA accessibility, metabolic control, receptor trafficking and immune-cell responses to characteristic evidence combinations for each state. Radiation, chemotherapy, poly(ADP-ribose) polymerase (PARP) inhibition, immune checkpoint blockade (ICB), STING agonism and ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibition address different constraints within this circuit. Mixed regional profiles are retained rather than forced into a single category. We distinguish baseline assignment, treatment-associated pharmacodynamics and independent clinical outcomes, and outline an adaptive research workflow. The framework offers testable explanations for conflicting pathway readouts, but requires assay standardisation and prospective validation before it can guide clinical treatment assignment.
Related
- Soluble N-terminal EphA2 fragment as a diagnostic biomarker and functional mediator of tumor progression in triple-negative breast cancer.
- Burnout- and Depression-Like Functional Collapse States — A Within-Person Biomarker Framework for Precision Psychiatry: State-Dependent Multisystem Regulation in High Processing Cost Phenotypes (HPCPh)
- From pose estimation accuracy to motor biomarker reliability: a reliability-centred evaluation framework for markerless movement analysis
- Integrative Single-Cell Transcriptomics and Explainable AI for Disease Mechanism and Biomarker Discovery in Triple-Negative Breast Cancer
- Integrating multi-omics with machine learning: from genomic variant functional annotation to pharmacogenomics and biomarker discovery
BibTeX
@article{song2026cgassting,
title = {{cGAS–STING signalling in triple-negative breast cancer: a functional-state framework for biomarker-guided intervention}},
author = {Jialu Song and Xiaohui Wang and Xiaotao Zhu},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.2028675},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2028675},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - cGAS–STING signalling in triple-negative breast cancer: a functional-state framework for biomarker-guided intervention
AU - Jialu Song
AU - Xiaohui Wang
AU - Xiaotao Zhu
PY - 2026
DA - 2026/11/05
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.2028675
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2028675
AB - Triple-negative breast cancer (TNBC) combines genomic instability with heterogeneous immune responses. Cyclic GMP–AMP synthase (cGAS) detects mislocalised DNA and produces cyclic guanosine monophosphate–adenosine monophosphate (cGAMP), which activates stimulator of interferon genes (STING). The resulting response can support antigen presentation or sustain inflammatory adaptation. This review interprets these divergent effects through four non-exclusive functional states: immune-productive activation, tumour-intrinsic attenuation, chronic inflammatory rewiring and extracellular cGAMP-restricted signalling. We connect DNA accessibility, metabolic control, receptor trafficking and immune-cell responses to characteristic evidence combinations for each state. Radiation, chemotherapy, poly(ADP-ribose) polymerase (PARP) inhibition, immune checkpoint blockade (ICB), STING agonism and ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibition address different constraints within this circuit. Mixed regional profiles are retained rather than forced into a single category. We distinguish baseline assignment, treatment-associated pharmacodynamics and independent clinical outcomes, and outline an adaptive research workflow. The framework offers testable explanations for conflicting pathway readouts, but requires assay standardisation and prospective validation before it can guide clinical treatment assignment.
SN - 1664-3224
ER -